Of note, further stratification of AML patients in primitive (M0-M2) vs. committed subtypes (M4-M5) potentiates the predictive power of the ATP1A1/BCL2L1 ratio (Fig. 2C). The gene discussed is ATP1A1; the disease is acute myeloid leukemia.